TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced its financial results for the first half of 2026. Key Developments in the Consolidated Financial Statements As mentioned in the announcement of half-year revenue on August 27, the business